Q1 2025 agilon health inc Earnings Call Transcript

May 6, 2025 / 08:30 PM GMT

Release Date Price: $111.5 (+8.25%)

Transcript 10-Q8-K

Key Points

Positve

Agilon Health Inc (AGL) reported membership revenue, medical margin, and adjusted EBITDA in line with their Q1 guidance range, maintaining their trajectory for full-year 2025 guidance.
The company has made significant progress in strengthening its network and enhancing its platform through advancements in technology, clinical pathways, and operating efficiency.
Agilon Health Inc (AGL) has successfully reduced its exposure to Medicare Part D, with less than 30% of its membership carrying Part D risk in 2025.
The company is optimistic about 2026, with a 280 basis point increase in the final rate notice from CMS, which addresses high cost and utilization trends.
Agilon Health Inc (AGL) continues to maintain cost discipline while investing in technology and clinical programs to support medical margin and patient outcome improvements.

Negative

The company experienced a slight year-over-year decline in Medicare Advantage membership, driven by previously disclosed partner exits and a smaller 2025 class.
Medical costs for the first quarter of 2025 were driven by continued elevated utilization, incremental flu-related costs, and negative prior period development.
Agilon Health Inc (AGL) reported a negative prior period development of $22 million, impacting their financial results.
The company is operating in a challenging environment with ongoing utilization pressures in areas such as inpatient services and Part B drug spend.
Agilon Health Inc (AGL) expects a headwind from the full implementation of LV. 28 in 2026, which will impact their financial performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AGL.N - agilon health Inc
Q1 2025 agilon health inc Earnings Call
May 06, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
We are.

Yes.

Hello, everybody, and welcome to the actual on Health First Quarter 2025 earnings conference call.

My name is Alicia, and I'll be your coordinator today.

If you would like to register a question Jen stage event, please press star one on your telephone keypad.

Now to hand over to Evan Smith, Senior Vice President, Investor Relations.

Please go ahead.

Thank you, operator.

Good afternoon and welcome to the call.

With me is our CEO, Steve Zhang, our CFO.

Jeff, you want to give Following our prepared remarks, we will conduct the Q&A session.

Before we begin, I'd like to remind you that our remarks and responses to questions

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.